P53 Deficiency Accelerate Esophageal Epithelium Intestinal Metaplasia Malignancy

Barrett’s esophagus (BE) is a precancerous lesion of esophageal adenocarcinoma (EAC). It is a pathological change in which the squamous epithelium distal esophagus is replaced by columnar epithelium. Loss of P53 is involved in the development of BE and is taken as a risk factor for the progression. We established a HET1A cell line with P53 stably knockdown by adenovirus vector infection, followed by 30 days of successive acidic bile salt treatment. MTT, transwell assay, and wound closure assay were applied to assess cell proliferation and migration ability. The expression of key factors was analyzed by RT-qPCR, western blotting and immunohistochemical staining. Our data show that the protein expression level of P53 reduced after exposure to acidic bile salt treatment, and the P53 deficiency favors the survival of esophageal epithelial cells to accommodate the stimulation of acidic bile salts. Furthermore, exposure to acidic bile salt decreases cell adhesions by repressing the JAK/STAT signaling pathway and activating VEGFR/AKT in P53-deficient esophageal cells. In EAC clinical samples, P53 protein expression is positively correlated with that of ICAM1 and STAT3 and negatively correlated with VEGFR protein expression levels. These findings elucidate the role of P53 in the formation of BE, explain the mechanism of P53 deficiency as a higher risk of progression for BE formation, and provide potential therapeutic targets for EAC.

[1]  S. Spechler,et al.  Mechanisms and pathophysiology of Barrett oesophagus , 2022, Nature Reviews Gastroenterology & Hepatology.

[2]  S. Sihag,et al.  The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Suyong Choi,et al.  A p53-Phosphoinositide Signalosome Regulates Nuclear Akt Activation , 2021, bioRxiv.

[4]  Xiaoying Hu,et al.  The JAK/STAT signaling pathway: from bench to clinic , 2021, Signal Transduction and Targeted Therapy.

[5]  S. Killcoyne,et al.  Evolution and progression of Barrett’s oesophagus to oesophageal cancer , 2021, Nature Reviews Cancer.

[6]  Yuquan Wei,et al.  Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment , 2021, Cell proliferation.

[7]  A. Thrift Global burden and epidemiology of Barrett oesophagus and oesophageal cancer , 2021, Nature Reviews Gastroenterology & Hepatology.

[8]  J. Lagergren,et al.  Gastroesophageal Reflux Disease. , 2020, JAMA.

[9]  A. Bass,et al.  Abnormal TP53 Predicts Risk of Progression in Patients With Barrett’s Esophagus Regardless of a Diagnosis of Dysplasia , 2020, medRxiv.

[10]  S. Killcoyne,et al.  Genomic copy number predicts esophageal cancer years before transformation , 2020, Nature Medicine.

[11]  D. Tweardy,et al.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution , 2020, Pharmacological Reviews.

[12]  P. V. van Dam,et al.  The potential and controversy of targeting STAT family members in cancer. , 2020, Seminars in cancer biology.

[13]  V. Jobanputra,et al.  High‐resolution genomic alterations in Barrett's metaplasia of patients who progress to esophageal dysplasia and adenocarcinoma , 2019, International journal of cancer.

[14]  Yonne Peters,et al.  Barrett oesophagus , 2019, Nature Reviews Disease Primers.

[15]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[16]  M. Bulyk,et al.  The multiple mechanisms that regulate p53 activity and cell fate , 2019, Nature Reviews Molecular Cell Biology.

[17]  Wei Zhang,et al.  Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett's Cells. , 2019, Gastroenterology.

[18]  Nicholas D. Camarda,et al.  Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. , 2018, Gastroenterology.

[19]  Jing Yan,et al.  Targeting VEGF/VEGFR to Modulate Antitumor Immunity , 2018, Front. Immunol..

[20]  A. Thrift Barrett’s Esophagus and Esophageal Adenocarcinoma: How Common Are They Really? , 2018, Digestive diseases and sciences.

[21]  C. Caldas,et al.  Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. , 2017, Gastroenterology.

[22]  J. Lagergren,et al.  The Epidemiology of Esophageal Adenocarcinoma. , 2017, Gastroenterology.

[23]  S. Imbeaud,et al.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.

[24]  Scott W. Lowe,et al.  Putting p53 in Context , 2017, Cell.

[25]  Geet Duggal,et al.  Salmon: fast and bias-aware quantification of transcript expression using dual-phase inference , 2017, Nature Methods.

[26]  P. Taylor,et al.  Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort , 2017, Gut.

[27]  P. Thota,et al.  Expression of p53 predicts risk of prevalent and incident advanced neoplasia in patients with Barrett's esophagus and epithelial changes indefinite for dysplasia , 2015, Gastroenterology report.

[28]  J. Wilson,et al.  Gastroesophageal Reflux Disease , 2008, North Carolina Medical Journal.

[29]  A. Gavin,et al.  Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5. , 2015, European journal of cancer.

[30]  P. Fockens,et al.  Aberrant TP53 detected by combining immunohistochemistry and DNA‐FISH improves Barrett's esophagus progression prediction: A prospective follow‐up study , 2015, Genes, chromosomes & cancer.

[31]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[32]  E. Kuipers,et al.  Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus , 2012, Gut.

[33]  W. El-Rifai,et al.  Glutathione peroxidase 7 protects against oxidative DNA damage in oesophageal cells , 2011, Gut.

[34]  H. Sørensen,et al.  Incidence of adenocarcinoma among patients with Barrett's esophagus. , 2011, The New England journal of medicine.

[35]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[36]  S. Spechler,et al.  Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. , 2010, Gastroenterology.

[37]  R. Sutton,et al.  TP53 mutations in malignant and premalignant Barrett's esophagus. , 2003, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[38]  S. Spechler Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. , 2002, Gastroenterology.

[39]  D. Hicklin,et al.  Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.

[40]  H Feussner,et al.  Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. , 1997, Surgery.

[41]  D. Gotley,et al.  Composition of gastro-oesophageal refluxate. , 1991, Gut.